In-vitro Activity of Avermectins against Mycobacterium ulcerans

PLoS Neglected Tropical Diseases

Volumn 9, Issue 3, 2015, Pages

  Omansen, Till F ^a,b   Porter, Jessica L ^a   Johnson, Paul D R ^a,c   van der Werf, Tjip S ^b   Stienstra, Ymkje ^b   Stinear, Timothy P ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; MOXIDECTIN; RIFAMPICIN; AVERMECTIN; STREPTOMYCIN;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BURULI ULCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM MARINUM; MYCOBACTERIUM ULCERANS; NONHUMAN; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; BURULI ULCER; IVERMECTIN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN;

EID: 84928795316     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003549     Document Type: Article

References (22)

1. van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, et al. (2005) Mycobacterium ulcerans disease. Bull World Health Organ 83: 785–791. 16283056
2. Sizaire V, Nackers F, Comte E, Portaels F, . (2006) Mycobacterium ulcerans infection: Control, diagnosis, and treatment. Lancet Infect Dis 6: 288–296. 16631549
3. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K, . (1999) Mycobacterium ulcerans infection. Lancet 354: 1013–1018. 10501380
4. Alferink M, van der Werf TS, Sopoh GE, Agossadou DC, Barogui YT, et al. (2013) Perceptions on the effectiveness of treatment and the timeline of buruli ulcer influence pre-hospital delay reported by healthy individuals. PLoS Negl Trop Dis 7: e2014. doi: 10.1371/journal.pntd.0002014 23350009
5. Stienstra Y, van der Graaf WT, Asamoa K, van der Werf TS, . (2002) Beliefs and attitudes toward buruli ulcer in ghana. Am J Trop Med Hyg 67: 207–213. 12389949
6. Stienstra Y, van Roest MH, van Wezel MJ, Wiersma IC, Hospers IC, et al. (2005) Factors associated with functional limitations and subsequent employment or schooling in buruli ulcer patients. Trop Med Int Health 10: 1251–1257. 16359405
7. Barogui Y, Johnson RC, van der Werf TS, Sopoh G, Dossou A, et al. (2009) Functional limitations after surgical or antibiotic treatment for buruli ulcer in benin. Am J Trop Med Hyg 81: 82–87. 19556571
8. Einarsdottir T, Huygen K, . (2011) Buruli ulcer. Hum Vaccin 7: 1198–1203. doi: 10.4161/hv.7.11.17751 22048117
9. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the combination rifampin-streptomycin in preventing growth of mycobacterium ulcerans in early lesions of buruli ulcer in humans. Antimicrob Agents Chemother 49: 3182–3186. 16048922
10. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited mycobacterium ulcerans infection: A randomised controlled trial. Lancet 375: 664–672. doi: 10.1016/S0140-6736(09)61962-0 20137805
11. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029–4035. 17526760
12. Klis S, Ranchor A, Phillips RO, Abass KM, Tuah W, et al. (2014) Good quality of life in former buruli ulcer patients with small lesions: Long-term follow-up of the BURULICO trial. PLoS Negl Trop Dis 8: e2964. doi: 10.1371/journal.pntd.0002964 25010061
13. Klis S, Stienstra Y, Phillips RO, Abass KM, Tuah W, et al. (2014) Long term streptomycin toxicity in the treatment of buruli ulcer: Follow-up of participants in the BURULICO drug trial. PLoS Negl Trop Dis 8: e2739. doi: 10.1371/journal.pntd.0002739 24625583
14. Friedman ND, Athan E, Hughes AJ, Khajehnoori M, McDonald A, et al. (2013) Mycobacterium ulcerans disease: Experience with primary oral medical therapy in an australian cohort. PLoS Negl Trop Dis 7: e2315. doi: 10.1371/journal.pntd.0002315 23875050
15. Lim LE, Vilcheze C, Ng C, Jacobs WR, JrRamon-Garcia S, et al. (2013) Anthelmintic avermectins kill mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother 57: 1040–1046. doi: 10.1128/AAC.01696-12 23165468
16. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, et al. (2010) Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5: e10777. doi: 10.1371/journal.pone.0010777 20520722
17. Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL, . (2013) Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent mycobacterium ulcerans infection. PLoS Negl Trop Dis 7: e2598. doi: 10.1371/journal.pntd.0002598 24367713
18. Stinear TP, Seemann T, Harrison PF, Jenkin GA, Davies JK, et al. (2008) Insights from the complete genome sequence of mycobacterium marinum on the evolution of mycobacterium tuberculosis. Genome Res 18: 729–741. doi: 10.1101/gr.075069.107 18403782
19. Stinear TP, Seemann T, Pidot S, Frigui W, Reysset G, et al. (2007) Reductive evolution and niche adaptation inferred from the genome of mycobacterium ulcerans, the causative agent of buruli ulcer. Genome Res 17: 192–200. 17210928
20. P-glycoprotein/ABCB1 substrates / P-glycoprotein/ABCB1 inducers. in lexi-Comp Online™ Interaction monograph. Hudson (OH). Accessed online 5 dec 2014.
21. Muhammed Ameen S, Drancourt M, . (2013) Ivermectin lacks antituberculous activity. J Antimicrob Chemother 68: 1936–1937. doi: 10.1093/jac/dkt089 23587653
22. Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, et al. (1996) Ivermectin distribution in the plasma and tissues of patients infected with onchocerca volvulus. Eur J Clin Pharmacol 50: 407–410. 8839664